98%
921
2 minutes
20
Sensorineural hearing loss (SNHL), characterized by damage to the inner ear or auditory nerve, is a prevalent auditory disorder. This study explores the potential of (CAE) as a therapeutic agent for SNHL. In vivo experiments were conducted using zebrafish and mouse models. Zebrafish with neomycin-induced ototoxicity were treated with CAE, resulting in otic hair cell protection with an EC of 0.49 µg/mL and a therapeutic index of 1020. CAE treatment improved auditory function and protected cochlear sensory cells in a mouse model after noise-induced hearing loss (NIHL). RNA sequencing of NIHL mouse cochleae revealed that CAE up-regulates genes involved in neurotransmitter synthesis, secretion, transport, and neuronal survival. Real-time qPCR validation showed that NIHL decreased the mRNA expression of genes related to neuronal function, such as , , , , , and , while the CAE treatment significantly elevated these levels. In conclusion, our findings provide strong evidence that CAE protects against hearing loss by promoting sensory cell protection and enhancing the expression of genes critical for neuronal function and survival.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11357119 | PMC |
http://dx.doi.org/10.3390/nu16162716 | DOI Listing |
J Voice
September 2025
Department of Speech-Language-Hearing Sciences, Medical School, Federal University of Minas Gerais - UFMG, Belo Horizonte, Minas Gerais, Brazil. Electronic address:
Objective: To analyze the association between the risk of voice disorders and sociodemographic, work, and general health factors in urban and rural school teachers.
Methods: This is an observational, cross-sectional, analytical study with 1705 teachers from urban schools and 202 from rural schools teaching elementary and high school in Minas Gerais, Brazil. The exclusion criteria were being retired or no longer teaching and/or not accepting to participate in the study.
Med Eng Phys
October 2025
Department of Bioengineering, Technological University of Havana "José Antonio Echeverría", Cuba.
Congenital hearing loss is a significant health problem, with a worldwide incidence of >6 per 1000 live births. Late diagnosis will delay appropriate treatment, leading to potential neurodevelopment problems. Early diagnosis requires neonatal hearing screening, where one of the most used techniques is automated Auditory Brainstem Responses (aABR).
View Article and Find Full Text PDFAJNR Am J Neuroradiol
September 2025
From the Department of Otorhinolaryngology Head and Neck Surgery (J.G., Y.L., S.G.) and Department of Radiology (N.X., R.T., H.D.,Z.Y., Z.W., P.Z.), Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Background And Purpose: Isolated congenital middle ear malformation contributes significantly to congenital hearing loss and growth problems. This study aims to compare 0.1 mm isotropic ultra-high-resolution computed tomography and conventional high-resolution computed tomography for assessing isolated congenital middle ear malformation, using surgical exploration as the gold standard.
View Article and Find Full Text PDFAerosp Med Hum Perform
September 2025
Introduction: The rapidly expanding commercial spaceflight (CSF) market has fueled increasing interest in spaceflight experiences among individuals without professional astronaut qualifications. Such individuals may present with a range of medical conditions that add uncertainties to medical preparation and risk assessment for spaceflight. As the ear, nose, and throat (ENT) working group of the Aerospace Medical Association Ad Hoc Committee on Commercial Spaceflight, we conducted a scoping review to assess the available biomedical literature for ENT and neuro-vestibular conditions and physiology pertinent to spaceflight for nonprofessional space travelers.
View Article and Find Full Text PDFJMIR Res Protoc
September 2025
Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Background: Cancer screening nonadherence persists among adults who are deaf, deafblind, and hard of hearing (DDBHH). These barriers span individual, clinician, and health care system levels, contributing to difficulties understanding cancer information, accessing screening services, and following treatment directives. Critical communication barriers include ineffective patient-physician communication, limited access to American Sign Language (ASL) cancer information, misconceptions about medical procedures, insurance navigation difficulties, and intersectional barriers for multiply marginalized individuals.
View Article and Find Full Text PDF